Nullifying the CDKN2AB locus promotes mutant K-ras lung tumorigenesis

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Lung adenocarcinomas frequently harbor KRAS mutations.
• The CDKN2AB locus, encoding p16INK4A, p14ARF, and p15INK4B, is often altered in lung cancer.
• The role of p15INK4B in KRAS-driven lung cancer remains largely uncharacterized.

Purpose of the Study:

• To investigate the frequency and functional significance of CDKN2AB loss in KRAS-mutant lung adenocarcinoma.
• To determine the specific contribution of p15INK4B to KRAS-driven lung tumorigenesis.

Main Methods:

• Analysis of The Cancer Genome Atlas (TCGA) database for CDKN2AB alterations in human lung adenocarcinoma.
• Utilizing genetically engineered mouse models (GEMMs) with mutant Kras and varying CDKN2A/CDKN2B genotypes.
• In vitro studies using human lung cancer cell lines with defined genetic backgrounds.

Main Results:

• Two-hit inactivation of CDKN2A and CDKN2B is common in KRAS-mutant lung adenocarcinoma.
• Complete loss of CDKN2AB significantly accelerates Kras-driven lung tumorigenesis in mice.
• Loss of CDKN2AB leads to increased proliferation, decreased differentiation, enhanced metastasis, and reduced survival.
• p15INK4B was identified as a critical tumor suppressor in this context.

Conclusions:

• Loss of CDKN2AB, including p15INK4B, plays a significant biological role in promoting aggressive lung adenocarcinoma.
• Mutant Kras;Cdkn2ab null mice serve as a valuable preclinical model for aggressive lung adenocarcinoma.
• These models can be used for testing novel therapeutic strategies.